Beyond Air initiated with a Buy at JonesResearch

JonesResearch initiated coverage of Beyond Air (XAIR) with a Buy rating and $1 price target Beyond Air is a commercial-stage medical device company whose systems deliver unlimited and on-demand nitric oxide from ambient air via ionization with its patented Plasma Pulse Technology, the analyst tells investors in a research note. The firm says the company has faced setbacks and challenges in its initial commercial efforts, which limited its ability to achieve substantial revenue to date. However, Jones believes Beyond Air is now well positioned to deliver on more substantial revenue growth targets with potential for broader market adoption following approval of its second generation LungFit PH system.